[{"id":"ed745a1a-e25b-481e-9a43-45f739d28d5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239092","created_at":"2021-01-18T20:36:34.133Z","updated_at":"2024-07-02T16:35:03.671Z","phase":"Phase 1","brief_title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","source_id_and_acronym":"NCT04239092","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • irinotecan • topotecan • elraglusib (9-ING-41) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-15"},{"id":"a0e00cfa-2eb4-4439-8a06-39293232dc5b","acronym":"Actuate 1801","url":"https://clinicaltrials.gov/study/NCT03678883","created_at":"2021-01-18T18:02:27.392Z","updated_at":"2024-07-02T16:35:15.452Z","phase":"Phase 2","brief_title":"9-ING-41 in Patients With Advanced Cancers","source_id_and_acronym":"NCT03678883 - Actuate 1801","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-11"},{"id":"78300dda-68e6-4423-8fb4-e493ba460a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04832438","created_at":"2021-04-05T12:53:00.094Z","updated_at":"2024-07-02T16:36:16.800Z","phase":"Phase 2","brief_title":"9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma","source_id_and_acronym":"NCT04832438","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • elraglusib (9-ING-41)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/18/2030","start_date":" 12/18/2030","primary_txt":" Primary completion: 06/18/2033","primary_completion_date":" 06/18/2033","study_txt":" Completion: 06/18/2034","study_completion_date":" 06/18/2034","last_update_posted":"2022-02-22"}]